Abstract-Modification of low density lipoprotein (LDL) by myeloperoxidase-generated HOCl has been implicated in human atherosclerosis. Incubation of LDL with HOCl generates several reactive intermediates, primarily N-chloramines, which may react with other biomolecules. In this study, we investigated the effects of HOCl-modified LDL on the activity of lecithin-cholesterol acyltransferase (LCAT), an enzyme essential for high density lipoprotein maturation and the antiatherogenic reverse cholesterol transport pathway. We exposed human LDL (0.5 mg protein/mL) to physiological concentrations of HOCl (25 to 200 mol/L) and characterized the resulting LDL modifications to apolipoprotein B and lipids; the modified LDL was subsequently incubated with apolipoprotein B-depleted plasma (density Ͼ1.063 g/mL fraction), which contains functional LCAT. Increasing concentrations of HOCl caused various modifications to LDL, primarily, loss of lysine residues and increases in N-chloramines and electrophoretic mobility, whereas lipid hydroperoxides were only minor products. LCAT activity was extremely sensitive to HOCl-modified LDL and was reduced by 23% and 93% by LDL preincubated with 25 and 100 mol/L HOCl, respectively. Addition of 200 mol/L ascorbate or N-acetyl derivatives of cysteine or methionine completely prevented LCAT inactivation by LDL preincubated with Յ200 mol/L HOCl. Protecting the free thiol groups of LCAT with 5,5Ј-dithio-bis-(2-nitrobenzoic acid) before exposure to HOCl-modified LDL, which inhibits lipid hydroperoxide-mediated inactivation of LCAT, failed to prevent the loss of enzyme activity. Our data indicate that N-chloramines from HOCl-modified LDL mediate the loss of plasma LCAT activity and provide a novel mechanism by which myeloperoxidase-generated HOCl may promote atherogenesis. xidative stress is thought to play a causal role in the pathogenesis of atherosclerosis. 1 Although there are many determinants in the development of an atherosclerotic lesion, substantial in vitro evidence links oxidized forms of LDL to molecular processes relevant to atherogenesis. 1 Recent in vitro and in vivo evidence suggests that myeloperoxidase (MPO) can oxidize LDL to an atherogenic form. Immunoreactive and catalytically active MPO has been found in human atherosclerotic lesions. 2 Moreover, a specific marker of MPO-catalyzed oxidation, 3-chlorotyrosine, is elevated 30-fold in LDL isolated from human lesions compared with plasma-derived LDL. 3 In addition, immunohistochemical studies have revealed the presence of HOClmodified proteins in human atherosclerotic lesions 4 and the colocalization of MPO and HOCl-modified proteins with monocyte/macrophages, endothelial cells, and the extracellular matrix. 5 A number of studies have also shown that HOCl-modified LDL exerts various pathophysiological effects on leukocytes and vascular cells. 6 -9 Thus, there is strong evidence for a role of MPO in LDL oxidation and human atherogenesis.
O xidative stress is thought to play a causal role in the pathogenesis of atherosclerosis. 1 Although there are many determinants in the development of an atherosclerotic lesion, substantial in vitro evidence links oxidized forms of LDL to molecular processes relevant to atherogenesis. 1 Recent in vitro and in vivo evidence suggests that myeloperoxidase (MPO) can oxidize LDL to an atherogenic form. Immunoreactive and catalytically active MPO has been found in human atherosclerotic lesions. 2 Moreover, a specific marker of MPO-catalyzed oxidation, 3-chlorotyrosine, is elevated 30-fold in LDL isolated from human lesions compared with plasma-derived LDL. 3 In addition, immunohistochemical studies have revealed the presence of HOClmodified proteins in human atherosclerotic lesions 4 and the colocalization of MPO and HOCl-modified proteins with monocyte/macrophages, endothelial cells, and the extracellular matrix. 5 A number of studies have also shown that HOCl-modified LDL exerts various pathophysiological effects on leukocytes and vascular cells. 6 -9 Thus, there is strong evidence for a role of MPO in LDL oxidation and human atherogenesis.
MPO is a heme-containing enzyme, released from activated neutrophils and monocytes, that catalyzes the production of strong oxidants. 10 The predominant product of this enzyme at physiological chloride ion concentrations is HOCl, 11 an oxidant that readily reacts with a variety of biomolecules, such as thiols, thioethers, ascorbate, and amines, including amino acids. 12 Because of the high reactivity of HOCl, its reactions are dependent on the relative concentrations and reactivities of compounds in the immediate vicinity. Thiols and methionine residues are manyfold more reactive with HOCl than are other amino acids and amines. 12 At neutral pH, reagent or MPO-generated HOCl preferentially oxidizes the apoB moiety of LDL. 13, 14 Neither LDL-associated lipids nor antioxidants (eg, ␣-tocopherol and ␤-carotene) appear to be major targets of HOCl. 14, 15 Of the various amino acid residues in apoB modified by HOCl, lysine residues quantitatively represent the major target. 13, 14 The reaction of HOCl with the ⑀-amino group of lysine residues results in the formation of N-chloramines (reaction 1). Lysine chloramines can decompose to form aldehydes (reaction 2) and/or react directly with free thiols and/or methionine residues. 16 The reactions are as follows: reaction 1, R-CH 2 -NH 2 ϩHOCl3 R-CH 2 -NHClϩH 2 O; reaction 2, R-CH 2 -NHClϩH 2 O3 R-CHϭOϩNH 4 ϩ ϩCl Ϫ . It has been suggested that lysine chloramine-derived aldehydes participate in HOCl-induced cross-linking of apoB and aggregation of LDL, 14 which result in the conversion of LDL to a ligand for the scavenger receptors of macrophages. 13, 17 However, it is important to note that lysine chloramines are more likely to react with free thiols and/or methionine residues 16 than to decompose to aldehydes. The specificity of the former reactions suggests that biomolecules possessing biologically active cysteine and/or methionine residues may be inactivated by HOCl-modified LDL. Thus, unlike lipoxygenase-dependent or metal ion-dependent modifications of LDL, which involve the derivatization of lysine residues by lipid hydroperoxide breakdown products, 1 HOCl directly modifies apoB lysine residues to N-chloramines, which may enhance the atherogenicity of LDL in a number of ways.
Lecithin-cholesterol acyltransferase (LCAT), an enzyme essential for HDL maturation and the antiatherogenic reverse cholesterol transport pathway, 18 has 2 free cysteine residues that can modulate enzymatic activity. 19 It has been demonstrated that LCAT loses activity when exposed to copper-oxidized LDL or lipoxygenase-generated hydroperoxides. 20 -22 The mechanism of this inactivation is thought to involve adduct formation between aldehydic lipid hydroperoxide breakdown products and the free cysteine residues of LCAT. 22, 23 Considering the lability of LCAT when it is exposed to thiol-specific reagents, we hypothesized that HOCl-modified LDL may impair LCAT function through the facile reaction of N-chloramines with free thiols.
Methods

Materials
ApoA-I was isolated from human plasma and purified as previously described. 24 Egg L-␣-phosphatidylcholine was purchased from Avanti Polar Lipids, and [4- 14 C]cholesterol was obtained from NEN Products. Human leukocyte MPO and HOCl were obtained from Calbiochem and Aldrich, respectively. 7-Fluorobenzo-2-oxa-1,3-diazole-4-sulfonamide (ABD-F) was from Molecular Probes. PD-10 gel filtration columns were from Pharmacia Biotech. All other reagents were from Sigma Chemical Co. All solvents were high-performance liquid chromatography (HPLC) grade. PBS was composed of 10 mmol/L sodium phosphate buffer, 140 mmol/L NaCl, and 100 mol/L diethylenetriamine pentaacetic acid, pH 7.4.
Lipoprotein Isolation
Blood was obtained with informed consent from fasted volunteers. Heparin was used to prevent coagulation, and plasma was separated from cellular blood components by low-speed centrifugation (1200g, 4°C, 20 minutes). Lipoproteins (LDL, density [d]ϭ1.019 to 1.063 g/mL; HDL, dϭ1.063 to 1.21 g/mL) were rapidly isolated from plasma by preparative sequential ultracentrifugation with use of an Optima-TL ultracentrifuge and a TLA-100.4 rotor (Beckman Instruments). Standard methods 25 were used, but corrections were made for the higher gravitational forces generated by the Optima ultracentrifuge and the shorter path length of the TLA-100.4 rotor. Isolated lipoproteins were desalted by gel filtration with the use of PD-10 columns equilibrated with PBS. The protein content of isolated lipoproteins was determined by using the Lowry Micro Method Kit (Sigma P5656). The dϾ1.063 g/mL fraction of plasma (containing LCAT, HDL, and non-apoB plasma proteins) and lipoproteindepleted plasma were isolated after a single ultracentrifugation step and dialyzed into PBS.
LDL Incubations With HOCl
HOCl was standardized at 292 nm [⑀ϭ350 (mol/L) Ϫ1 · cm Ϫ1 ] as previously described. 26 Bolus HOCl was added with gentle mixing to LDL (0.5 mg protein/mL) in PBS; incubations were carried out for 30 minutes at 37°C. Final HOCl concentrations ranged from 25 to 200 mol/L, corresponding to HOCl:apoB molar ratios from 25:1 to 200:1. Modified LDL was kept on ice (for Ͻ1 hour) until characterized and used in incubations containing LCAT.
Characterization of LDL Protein Modifications
Unmodified lysine residues were assessed by fluorescamine fluorescence, 27 and loss of tryptophan residues was assessed directly by fluorescence (excitation 280 nm, emission 335 nm). 13 Loss of cysteine residues was monitored by fluorescence after derivatization with ABD-F. 16 All fluorometric measurements were performed by using a Hitachi F-2500 Fluorescence Spectrophotometer (Hitachi Instruments). N-Chloramines were measured by the thionitrobenzoic acid assay. 28 Changes in LDL charge characteristics, reflecting modification of lysine residues, were assessed by agarose gel electrophoresis. 16 
Determination of LDL Lipid Peroxidation
Thiobarbituric acid-reactive substances (TBARS) in LDL were measured by the method of Kosugi et al. 29 Cholesteryl ester hydroperoxide content of LDL was determined, as previously described, 30 by use of a specific and sensitive method with HPLC separation and post-column chemiluminescence detection. Vitamin E was assessed by HPLC with electrochemical detection as previously described. 30 
Incubations of HOCl-Modified LDL With LCAT
Control and HOCl-modified LDLs were added to the dϾ1.063 g/mL fraction of human plasma (containing HDL, LCAT, and plasma proteins) and incubated at 37°C for 30 minutes. Preliminary studies demonstrated that LCAT inactivation was complete within 15 minutes, and incubations lasting Ͼ30 minutes did not result in additional loss of LCAT activity. The reconstituted plasma incubations contained 50 g of LDL protein and represented a 3-fold dilution of plasma with an LDL protein concentration of 1 mg/mL. In some experiments, ascorbate or the N-acetyl derivatives of cysteine, histidine, lysine, methionine, tryptophan, and tyrosine (final concentration 200 mol/L) were preincubated at 37°C for 30 minutes with HOCl-modified LDL. In other experiments, the dϾ1.063 g/mL fraction of plasma was incubated at 37°C for 30 minutes in the presence or absence of the reversible thiol-blocking reagent 5,5Ј-dithio-bis-(2-nitrobenzoic acid) (DTNB, 1.7 mmol/L); excess DTNB was subsequently removed by dialysis in PBS. LCAT activity was completely inhibited after this procedure and could be restored by the addition of 5 mmol/L ␤-mercaptoethanol.
Assessment of LCAT Activity
LCAT activity was measured by the exogenous "common substrate" (ie, proteoliposome) method of Chen and Albers. 31 This method uses an excess of [
14 C]cholesterol-labeled proteoliposome substrate composed of human apoA-I:egg-yolk phosphatidylcholine:unesterified cholesterol at a molar ratio of 0.8:250:12.5. The assay is dependent on the amount of active LCAT and independent of endogenous plasma substrates and cofactors. In addition to the proteoliposome substrate, LCAT reaction mixtures contained 20 mmol/L Tris HCl (pH 8.0), 0.15 mol/L NaCl, 0.27 mmol/L EDTA, 0.5% human serum albumin, and 5 mmol/L ␤-mercaptoethanol. Aliquots (40 L) of reconstituted plasma (ie, mixtures of control or HOCl-modified LDL with the dϾ1.063 g/mL fraction) were added to start the reaction; incubations were carried out for 30 minutes at 37°C. The reaction was terminated by the addition of ethanol (final concentration 50%). After hexane extraction, the labeled reaction product ([ 14 
Results
Characterization of HOCl-Modified LDL
As previously reported by us, 16 treatment of LDL with increasing concentrations of HOCl (25 to 200 mol/L) resulted in dose-dependent oxidation of apoB cysteine, tryptophan, and lysine residues (Table) . Because apoB contains approximately 4 cysteine, 37 tryptophan, and 356 lysine residues, 32 these data suggest that thiols are more sensitive to modification by HOCl than are tryptophan residues and that tryptophan residues are more sensitive than are lysine residues. A small increase in the electrophoretic mobility of LDL was also observed (1.5-fold at 200 mol/L HOCl, Table) and is likely the result of HOCl-induced lysine modification. As expected, the decrease in apoB lysine residues and the increase in LDL electrophoretic mobility reflect the incremental increases in formation of N-chloramines (Table) . Similar modifications were observed by using MPO/H 2 O 2 / Cl Ϫ to generate HOCl instead of adding reagent HOCl (data not shown).
Effects of HOCl-Modified LDL on LCAT Activity
Incubation of HOCl-modified LDL with the dϾ1.063 g/mL fraction of human plasma (containing HDL, LCAT, and plasma proteins) resulted in dose-dependent inactivation of LCAT activity (Figure 1) , as determined by the exogenous "common substrate" (ie, proteoliposome) method. 31 Whereas native LDL had no effect on LCAT activity, LDL modified with 100 mol/L HOCl reduced LCAT activity by almost 100% (Figure 1) . Similar results were obtained with LDL modified by MPO/H 2 O 2 /Cl Ϫ (data not shown). It should be noted that 100 mol/L HOCl is within the physiological range of HOCl, ie, Յ200 mol/L. 33, 34 A similar inactivation of LCAT activity was observed when HOCl-treated HDL was added to lipoprotein-deficient plasma (dϾ1.21 g/mL, data not shown). Because the method used to measure LCAT activity in these experiments is thought to be independent of endogenous substrates, it is unlikely that oxidative modification of HDL-associated apoA-I can account for the loss of enzymatic activity observed. In contrast to HOCl-modified lipoproteins, HOCl-modified BSA had very little effect on LCAT activity. In 2 independent experiments, incubation of the dϾ1.063 g/mL fraction of plasma with 0.5 mg/mL BSA treated with 25 to 200 mol/L HOCl resulted in a maximal decrease in LCAT activity by only 13%. These data suggest that the reactive component(s) responsible for inactivation of LCAT is specific to lipoproteins and/or that there is a specific interaction between LCAT and the lipoproteins that does not occur with BSA.
Role of N-Chloramines in LCAT Inactivation by HOCl-Modified LDL
To determine the reactive species associated with HOClmodified LDL and the possible amino acid target(s) on LCAT, ascorbate and several N-acetylated amino acids were incubated with HOCl-modified LDL before its addition to the LCAT-containing samples (Figure 2) . The sulfur-containing amino acids cysteine and methionine (200 mol/L each) Values are meanϮSD (nϭ4). Ultracentrifugally isolated human LDL was incubated with varying concentrations of HOCl ranging from 25 to 200 mol/L, corresponding to HOCl:apoB molar ratios of 25:1 to 200:1. Decreases in LDL-associated cysteine (Cys), tryptophan (Trp), and lysine (Lys) residues were assessed fluorometrically and were determined by assuming 4, 37, and 356 Cys, Trp, and Lys residues per LDL particle, respectively. 32 Increases in LDL-associated N-chloramines (RNHCl) were calculated by the thionitrobenzoic acid assay, and percentage increases in the net negative charge of LDL (ie, increases in anodic mobility) were assessed by agarose gel electrophoresis with Beckman Paragon Lipo-gels. REM indicates relative electrophoretic mobility. significantly inhibited inactivation of LCAT by HOClmodified LDL (Figure 2A ). In contrast, the N-acetyl derivatives of tryptophan, lysine, histidine, and tyrosine (200 mol/L each) did not exert any significant effect on inactivation of LCAT by HOCl-modified LDL ( Figure 2B ). These data mimic the reactivity of model N-chloramines, such as N-acetyl-lysine chloramine, toward these amino acids. 16 Preincubation of HOCl-modified LDL with 200 mol/L ascorbate, which we have previously shown to reduce N-chloramines back to their parent amines, 16 also significantly inhibited the inactivation of LCAT (Figure 2A ). Higher concentrations of ascorbate (400 mol/L) completely prevented enzyme inactivation (data not shown). These data suggest that LDL-associated N-chloramines are the reactive species involved in inactivation of LCAT and that the likely target(s) on LCAT are cysteine and/or methionine residues.
Role of Lipid Hydroperoxides in LCAT Inactivation by HOCl-Modified LDL
Recent studies have reported that oxidized lipids, 20 in particular, lipid hydroperoxides, 21, 22 can inhibit LCAT activity. Thus, it is possible that lipid hydroperoxides rather than, or in addition to, N-chloramines are responsible for the inactivation of LCAT by HOCl-modified LDL. Treatment of LDL with increasing concentrations of HOCl resulted in a small dosedependent increase in lipid hydroperoxides, which was inhibited by the lipid-soluble antioxidant butylated hydroxytoluene (BHT), as shown in Figure 3A . In contrast, treatment of LDL with HOCl did not cause an increase in TBARS from background levels (Ϸ2 nmol/mg LDL protein, data not shown). Furthermore, no significant loss of vitamin E was observed in LDL exposed to concentrations of HOCl of up to 200 mol/L (data not shown), consistent with previous reports. 13, 14 HOCl-modified LDL containing BHT, and thus containing decreased levels of lipid hydroperoxides ( Figure 3A) , was equally potent in inhibiting LCAT activity as was HOClmodified LDL not containing BHT ( Figure 3B ). These data suggest that LDL-associated lipid hydroperoxides are not involved in the inactivation of LCAT by HOCl-modified LDL.
Involvement of Thiols in LCAT Inactivation by HOCl-Modified LDL
Because LCAT contains 2 free cysteine residues (Cys31 and Cys184) located in proximity to its active site, 19 it is possible that LDL-associated N-chloramines are inactivating the enzyme by oxidizing the thiols to sulfenic or sulfinic acids. Therefore, the LCAT-containing samples were preincubated with the reversible thiol-specific reagent DTNB to sterically block the active site of LCAT and prevent its free cysteine residues from reacting with HOCl-modified LDL. However, treatment of LCAT with DTNB failed to inhibit inactivation of the enzyme by HOCl-modified LDL (Figure 4 ). These data suggest that inactivation of LCAT by HOCl-modified LDL is thiol independent and may, therefore, involve oxidation of the methionine residues of LCAT.
Discussion
The present study demonstrates that HOCl-modified LDL inhibits plasma LCAT activity. The HOCl concentrations required for LDL modification to completely inhibit LCAT activity (ie, Ϸ100 to 150 mol/L) are well within the range considered physiologically relevant (ie, the levels generated extracellularly over a 30-minute period by 5ϫ10 6 neutrophils/ mL). 33, 34 Inactivation of LCAT by HOCl-modified LDL appears to be independent of lipid hydroperoxides and, at least in part, dependent on N-chloramines, inasmuch as ascorbate completely inhibited inactivation of the enzyme. Although HOCl could potentially inactivate LCAT directly, its reactivity is less selective than that of N-chloramines, which, as we have previously shown, react predominantly with thiols, methionine, and ascorbate. 16 Also, the association of LCAT with oxidatively modified lipoproteins may enhance inactivation of the enzyme by LDL-associated N-chloramines (see below).
Interestingly, inactivation of LCAT by LDL-associated chloramines does not appear to involve thiol modification but, rather, may involve oxidation of methionine residues. There are several lines of evidence in support of this notion: (1) reversible protection of the thiol groups of LCAT with DTNB did not inhibit inactivation of the enzyme by HOCl-modified LDL; (2) preincubation of HOCl-modified LDL with N-acetylmethionine protected against subsequent inactivation of LCAT; (3) methionine residues are the only other major proteinassociated targets, apart from thiol residues, that are readily oxidized by N-chloramines 16 ; and (4) preliminary experiments have shown that HOCl-modified LDL mediates inactivation of the methionine-dependent protein ␣ 1 -antiproteinase by an Nchloramine-dependent mechanism (see below).
Our data suggest that HOCl-modified LDL inhibits LCAT activity by a mechanism different from that proposed for LCAT inactivation by copper-oxidized LDL. 20, 22 In contrast to copperinduced oxidation of LDL, the HOCl concentrations used in the present study did not affect LDL-associated TBARS or vitamin E levels. Use of a sensitive HPLC-postcolumn chemiluminescence method 30 demonstrated that HOCl induced the formation of small amounts of lipid hydroperoxides. However, the levels of lipid hydroperoxides formed were not associated with a measurable increase in LCAT inactivation. It should be noted that copper-oxidized LDL containing 4 to 7 nmol TBARS/mg protein also contains substantial levels of lipid hydroperoxides (9 to 25 nmol/mg LDL protein; M.R. McCall, B. Frei, unpublished data, 2000) but reduces LCAT activity by only 50%. 4 The mechanism by which HOCl-modified LDL inhibits LCAT activity likely involves N-chloramines, which account for Ϸ30% of the HOCl added to LDL. The N-acetyl derivatives of cysteine and methionine, as well as ascorbate, effectively protected against inactivation of LCAT by HOCl-modified LDL. We have shown previously that both ascorbate and these sulfur-containing amino acids are effective scavengers of N-chloramines. 16 In contrast, the N-acetyl derivatives of tryptophan, lysine, histidine, and tyrosine, which cannot scavenge N-chloramines, 16 did not protect against LCAT inactivation.
Inactivation of LCAT by lipid hydroperoxides isolated from copper-oxidized LDL is thought to involve the free cysteine residues of LCAT. 22 Although N-chloramines react readily with thiol groups, 16 reversible blocking of the free cysteine residues of LCAT with DTNB did not protect against loss of enzyme activity by HOCl-modified LDL. Oxidation of the thiol groups to higher oxidation states, such as sulfenic or sulfinic acids, may not cause sufficient steric hindrance to inhibit the enzyme compared with derivatization of the thiols with DTNB. 19 Thus, we hypothesize that LDL-associated N-chloramines alter the enzymatic activity of LCAT by oxidizing methionine residues and thereby modifying protein conformation. Although N-acetyl histidine did not protect against inactivation of LCAT by HOCl-modified LDL, we cannot rule out the possibility that N-chloramines directly affect the amino acids in the catalytic site of LCAT (ie, aspartate, histidine, and serine 18 ). However, it is of particular interest to note that lipid hydroperoxides 35 and N-chloramines 16 can oxidize methionine residues. This suggests that LDL-associated protein modifications induced by HOCl and LDL-associated lipid modifications induced by copper or lipoxygenase ultimately contribute to LCAT inactivation via this common mechanism.
A number of proteins have been shown to be inactivated via N-chloramine-dependent oxidation of essential methionine residues to methionine sulfoxide. 36 In plasma, these include the protease inhibitors ␣ 1 -antiproteinase 37,38 and ␣ 2 -macroglobulin, 39, 40 as well as the fifth component of human complement. 41 Oxidation of the methionine residues was associated with conformational changes in some of the proteins. 39, 40 We have found that HOClmodified LDL also inactivates ␣ 1 -antiproteinase with an IC 50 of 58 mol/L HOCl used to modify LDL (0.5 mg protein/mL). This inactivation is presumably due to oxidation of the reactive site methionine residue in ␣ 1 -antiproteinase 42 by LDL-associated N-chloramines, inasmuch as preincubation of the HOCl-modified LDL with ascorbate almost completely abrogated inactivation of the protease inhibitor (A.C. Carr, B. Frei, unpublished data, 2001) .
The data of the present study indicate that the reaction of HOCl-modified LDL with LCAT is specific to lipoproteins. For example, HOCl-modified albumin did not inhibit LCAT, in contrast to HOCl-modified HDL. Because it is unlikely that N-chloramines formed on LDL transfer to HDL, where they react with LCAT, our data suggest that LCAT and LDL interact directly in the reconstituted plasma system. On the basis of binding affinities, Kosek et al 43 estimated that Ϸ20% of LCAT is bound to LDL in plasma. Indirect evidence for an association of LCAT with HOCl-modified LDL was obtained when reagent HOCl-mediated was compared with HOCl-modified LDLmediated inactivation of LCAT in whole plasma. Direct addition of 100 and 200 mol/L HOCl to plasma did not cause measurable inhibition of LCAT activity, whereas addition of LDL modified with 100 or 200 mol/L HOCl caused 9% and 19% inactivation of enzyme activity, respectively (M.R. McCall, A.C. Carr, B. Frei, unpublished data, 2000). The degree of LCAT inactivation by HOCl-modified LDL in whole plasma was less than that in reconstituted plasma, suggesting some protection by low molecular weight antioxidants, such as ascorbate. Thus, it would appear that a localized microenvironment within the artery wall in which antioxidant defenses have been depleted is the most likely site for LCAT inactivation by HOCl-modified LDL to occur in vivo.
HDL has antiatherogenic properties that are due to multiple functions in the reverse cholesterol transport pathway. 18 It facilitates the efflux and net transfer of excess cholesterol from atherosclerotic foam cells; it provides the activator (ie, apoA-I) and substrates (ie, cholesterol and phospholipids) for LCAT, the enzyme that maintains the concentration gradient along which foam cell-derived cholesterol flows; and it facilitates the transport of foam cell-derived cholesterol to the liver for reutilization or catabolism. 18 HOCl-modified HDL impairs cholesterol efflux from macrophages, 44 and we have now shown that HOClmodified LDL is a potent inhibitor of LCAT activity. Thus, HOCl-modified lipoproteins (HDL and LDL) may enhance atherosclerosis in part by impairing the antiatherogenic reverse cholesterol transport pathway.
Although the exact role of LCAT in human atherosclerosis and coronary artery disease remains to be established, a few studies have shown that LCAT activity is significantly reduced (24% to 50% of control individuals) in patients with coronary artery disease and in patients after myocardial infarction. 45 Furthermore, there is evidence that some cases of human LCAT deficiency are associated with premature atherosclerosis and coronary artery disease. 46 In summary, we have shown that inactivation of LCAT by HOCl-modified LDL is independent of lipid hydroperoxides but is, at least in part, dependent on N-chloramines. The small molecule antioxidant ascorbate, which eliminates N-chloramines, completely inhibited inactivation of the enzyme. Inhibition of LCAT activity by HOCl-modified LDL does not appear to involve thiol modification but may involve oxidation of methionine residues. The latter may result in conformational changes and subsequent LCAT inactivation, suggesting a novel additional mechanism by which MPOderived HOCl may accelerate atherosclerosis.
